靶向2型糖尿病缓解的当代临床视角
本文为小型综述,聚焦2型糖尿病缓解这一临床状态。文章指出,代谢手术、药物治疗和生活方式干预的进展使诱导缓解比以往更可行,并揭示了胰腺β细胞功能障碍中可逆成分的存在;但缓解可能不持久(随时间出现血糖复发),且缓解状态下β细胞功能未必正常化,临床沟通需谨慎权衡利弊。
要点
- 代谢手术、药物治疗与生活方式干预的进展使2型糖尿病缓解比以往更可行。
- 缓解状态提示β细胞功能障碍存在可逆成分,但缓解时β细胞功能未必正常化。
- 缓解可能并非永久,可随时间出现血糖复发,临床沟通需权衡利弊。
核心结论
- 部分2型糖尿病患者经医学干预或自发可出现代谢改善至接近正常血糖水平的持续状态,即糖尿病缓解,但该状态可能不永久并可随时间出现血糖复发。
- 缓解状态下β细胞功能可能未正常化,这提示对缓解的现有认识仍存在许多空白。
- 临床讨论缓解目标时需谨慎,并向患者清晰传达追求该结局的利与弊。
研究设计与样本
- 本文为小型综述(mini-review),检视了关于2型糖尿病缓解迅速增长的文献及其意义与局限。
- 原文未报告检索数据库、检索时间范围与纳入文献数量。
主要发现
- 代谢手术、药物治疗和生活方式干预方案的深刻进展使诱导缓解比以往更可行。
- 对缓解能力的增强揭示了新的病理生理学认识,包括驱动2型糖尿病慢性进展的胰腺β细胞功能障碍中存在可逆成分。
- 缓解可能不是永久的,可导致随时间出现血糖复发(glycemic relapse)。
- 在缓解状态下β细胞功能可能未正常化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缓解可能并非永久,可导致随时间出现血糖复发。
- 缓解状态下β细胞功能可能未正常化。
- 当前对缓解的认识存在许多空白,临床讨论须谨慎以清晰传达利弊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It has long been known that some patients with type 2 diabetes (T2DM) can experience sustained metabolic improvement to near-normal levels of glycemia either spontaneously or after medical intervention. Now recognized as remission of diabetes, this intriguing state is currently more feasible than ever before due to profound advances in metabolic surgery, pharmacologic therapy, and regimens of lifestyle modification. This enhanced capacity to induce remission has revealed new pathophysiologic insights, including the presence of a reversible component of the pancreatic beta-cell dysfunction that otherwise drives the chronic progressive nature of T2DM. In doing so, it has changed the therapeutic landscape by offering new potential management objectives and considerations for patients and providers. However, the excitement around these developments must also be tempered by the sobering realities of our current understanding of remission, including the recognition that this condition may not be permanent (resulting in glycemic relapse over time) and that beta-cell function may not be normalized in the setting of remission. These limitations highlight both the many gaps in our current understanding of remission and the caution with which clinical discussions must be handled for clear patient-directed communication of the pros and cons of targeting this outcome in practice. In this mini-review, we consider this rapidly growing literature, including its implications and its limitations, and thereby seek to provide objective balanced perspectives on targeting remission of T2DM in current clinical care.
引用
- Retnakaran R, Kashyap SR, Gerstein HC, et al. Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes. J Clin Endocrinol Metab. 2024. PMID: 38108415. doi:10.1210/clinem/dgad746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。